addressing cardiotoxicity concerns with the use of gilteritinib
Published 1 year ago • 59 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:57
addressing cardiovascular aes associated with btki treatment in patients with cll
-
3:19
addressing cardiotoxicity associated with btkis in patients with cll
-
1:54
therapeutic approaches in the front-line for patients with ptcl
-
2:27
addressing the unmet needs for patients with tp53-mutated aml
-
2:00
the incorporation of immunotherapy into frontline all treatment
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
2:09
real-world incidence of ibrutinib-related cardiotoxicity in cll: insights from the lls registry
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
2:47
all about gilteritinib: when is gilteritinib used to treat flt3-positive aml? #aml
-
2:41
can gilteritinib cure aml? #aml
-
3:15
developments in targeted aml therapies: venetoclax, quizartinib & gilteritinib
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
0:52
monitoring, diagnosing & managing cardiotoxicity in al amyloidosis
-
2:27
gilteritinib maintenance after allogeneic transplantation in flt3-mutated aml
-
1:58
unanswered questions that remain in flt3-mutated aml
-
1:03
late effect surveillance following allosct: the publication of new guidelines
-
1:59
optimizing the use of flt3 inhibitors in aml: sequencing, post-transplant maintenance & more
-
1:03
targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
-
1:34
australasian lymphoma alliance consensus practice statement on the diagnosis and management of fl
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t